Anti-asialo GM1 NK cell depleting antibody does not alter the development of bleomycin induced pulmonary fibrosis

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Monnier, Justin ^a,b   Zabel, Brian A ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; GAMMA INTERFERON; GANGLIOTETRAOSYLCERAMIDE; GANGLIOTETRAOSYLCERAMIDE ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 1BETA; PHOSPHOLIPID ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIBODY; CYTOKINE; GANGLIOSIDE GM1;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CELL INFILTRATION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE EXACERBATION; FEMALE; IN VIVO STUDY; LUNG FIBROSIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; T CELL DEPLETION; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; DRUG EFFECTS; IMMUNOLOGY; KINETICS; LUNG; LUNG LAVAGE; LYMPHOCYTE DEPLETION; METABOLISM; PATHOLOGY; SPLEEN;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES; BLEOMYCIN; BRONCHOALVEOLAR LAVAGE FLUID; CELL MOVEMENT; CYTOKINES; FEMALE; G(M1) GANGLIOSIDE; KILLER CELLS, NATURAL; KINETICS; LUNG; LYMPHOCYTE DEPLETION; MICE, INBRED BALB C; PULMONARY FIBROSIS; SPLEEN;

EID: 84903398860     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099350     Document Type: Article

References (40)

1. (2000) American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161: 646-664.
2. Bitterman PB, Rennard SI, Keogh BA, Wewers MD, Adelberg S, et al. (1986) Familial idiopathic pulmonary fibrosis. Evidence of lung inflammation in unaffected family members. The New England journal of medicine 314: 1343-1347. (Pubitemid 16122467)
3. Selman M, King TE, Pardo A (2001) Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Annals of internal medicine 134: 136-151. (Pubitemid 32096342)
4. Moore BB, Hogaboam CM (2008) Murine models of pulmonary fibrosis. American journal of physiology Lung cellular and molecular physiology 294: L152-160. (Pubitemid 351253350)
5. Wynn TA (2011) Integrating mechanisms of pulmonary fibrosis. The Journal of experimental medicine 208: 1339-1350.
6. Jiang D, Liang J, Hodge J, Lu B, Zhu Z, et al. (2004) Regulation of pulmonary fibrosis by chemokine receptor CXCR3. The Journal of clinical investigation 114: 291-299. (Pubitemid 39071634)
7. Melhem A, Muhanna N, Bishara A, Alvarez CE, Ilan Y, et al. (2006) Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. Journal of hepatology 45: 60-71. (Pubitemid 43850614)
8. Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, et al. (2006) Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 130: 435-452. (Pubitemid 43202042)
9. Horikawa M, Fujimoto M, Hasegawa M, Matsushita T, Hamaguchi Y, et al. (2006) E- and P-selectins synergistically inhibit bleomycin-induced pulmonary fibrosis. The American journal of pathology 169: 740-749. (Pubitemid 44411942)
10. Culley FJ (2009) Natural killer cells in infection and inflammation of the lung. Immunology 128: 151-163.
11. Kataoka S, Konishi Y, Nishio Y, Fujikawa-Adachi K, Tominaga A (2004) Antitumor activity of eosinophils activated by IL-5 and eotaxin against hepatocellular carcinoma. DNA and cell biology 23: 549-560. (Pubitemid 39244333)
12. Nishikado H, Mukai K, Kawano Y, Minegishi Y, Karasuyama H (2011) NK cell-depleting anti-asialo GM1 antibody exhibits a lethal off-target effect on basophils in vivo. Journal of immunology 186: 5766-5771.
13. Slifka MK, Pagarigan RR, Whitton JL (2000) NK markers are expressed on a high percentage of virus-specific CD8+ and CD4+ T cells. Journal of immunology 164: 2009-2015. (Pubitemid 30108757)
14. Trambley J, Bingaman AW, Lin A, Elwood ET, Waitze SY, et al. (1999) Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection. The Journal of clinical investigation 104: 1715-1722. (Pubitemid 30053188)
15. Wiltrout RH, Santoni A, Peterson ES, Knott DC, Overton WR, et al. (1985) Reactivity of anti-asialo GM1 serum with tumoricidal and non-tumoricidal mouse macrophages. Journal of leukocyte biology 37: 597-614. (Pubitemid 15096486)
16. Kasai M, Iwamori M, Nagai Y, Okumura K, Tada T (1980) A glycolipid on the surface of mouse natural killer cells. European journal of immunology 10: 175-180. (Pubitemid 10150628)
17. Zaldivar MM, Berres ML, Sahin H, Nellen A, Heinrichs D, et al. (2012) The chemokine receptor CXCR3 limits injury after acute toxic liver damage. Laboratory investigation; a journal of technical methods and pathology 92: 724-734.
18. Eckelhart E, Warsch W, Zebedin E, Simma O, Stoiber D, et al. (2011) A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. Blood 117: 1565-1573.
19. Jessen B, Maul-Pavicic A, Ufheil H, Vraetz T, Enders A, et al. (2011) Subtle differences in CTL cytotoxicity determine susceptibility to hemophagocytic lymphohistiocytosis in mice and humans with Chediak-Higashi syndrome. Blood 118: 4620-4629.
20. Kim JH, Kim HY, Kim S, Chung JH, Park WS, et al. (2005) Natural killer T (NKT) cells attenuate bleomycin-induced pulmonary fibrosis by producing interferon-gamma. The American journal of pathology 167: 1231-1241. (Pubitemid 41541410)
21. Ashcroft T, Simpson JM, Timbrell V (1988) Simple method of estimating severity of pulmonary fibrosis on a numerical scale. Journal of clinical pathology 41: 467-470. (Pubitemid 18098428)
22. Kumar P, Thakar MS, Ouyang W, Malarkannan S (2013) IL-22 from conventional NK cells is epithelial regenerative and inflammation protective during influenza infection. Mucosal immunology 6: 69-82.
23. Small CL, Shaler CR, McCormick S, Jeyanathan M, Damjanovic D, et al. (2010) Influenza infection leads to increased susceptibility to subsequent bacterial superinfection by impairing NK cell responses in the lung. Journal of immunology 184: 2048-2056.
24. Zhou G, Juang SW, Kane KP (2013) NK cells exacerbate the pathology of influenza virus infection in mice. European journal of immunology 43: 929-938.
25. Aono Y, Ledford JG, Mukherjee S, Ogawa H, Nishioka Y, et al. (2012) Surfactant protein-D regulates effector cell function and fibrotic lung remodeling in response to bleomycin injury. American journal of respiratory and critical care medicine 185: 525-536.
26. Gao B, Radaeva S, Park O (2009) Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. Journal of leukocyte biology 86: 513-528.
27. Tian Z, Chen Y, Gao B (2013) Natural killer cells in liver disease. Hepatology 57: 1654-1662.
28. Burdick MD, Murray LA, Keane MP, Xue YY, Zisman DA, et al. (2005) CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. American journal of respiratory and critical care medicine 171: 261-268.
29. Jiang D, Liang J, Campanella GS, Guo R, Yu S, et al. (2010) Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4. The Journal of clinical investigation 120: 2049-2057.
30. Tager AM, Kradin RL, LaCamera P, Bercury SD, Campanella GS, et al. (2004) Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10. American journal of respiratory cell and molecular biology 31: 395-404. (Pubitemid 39330949)
31. Tighe RM, Liang J, Liu N, Jung Y, Jiang D, et al. (2011) Recruited exudative macrophages selectively produce CXCL10 after noninfectious lung injury. American journal of respiratory cell and molecular biology 45: 781-788.
32. Chen ES, Greenlee BM, Wills-Karp M, Moller DR (2001) Attenuation of lung inflammation and fibrosis in interferon-gamma-deficient mice after intratracheal bleomycin. American journal of respiratory cell and molecular biology 24: 545-555. (Pubitemid 32442761)
33. Segel MJ, Izbicki G, Cohen PY, Or R, Christensen TG, et al. (2003) Role of interferon-gamma in the evolution of murine bleomycin lung fibrosis. American journal of physiology Lung cellular and molecular physiology 285: L1255-1262. (Pubitemid 37448796)
34. Wilson MS, Madala SK, Ramalingam TR, Gochuico BR, Rosas IO, et al. (2010) Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. The Journal of experimental medicine 207: 535-552.
35. King TE, Jr., Albera C, Bradford WZ, Costabel U, Hormel P, et al. (2009) Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 374: 222-228.
36. Koyama K (2002) NK1.1+ cell depletion in vivo fails to prevent protection against infection with the murine nematode parasite Trichuris muris. Parasite immunology 24: 527-533.
37. Gao K, Li X, Zhang L, Bai L, Dong W, et al. (2013) Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer letters 335: 463-471.
38. Stein-Streilein J, Guffee J (1986) In vivo treatment of mice and hamsters with antibodies to asialo GM1 increases morbidity and mortality to pulmonary influenza infection. Journal of immunology 136: 1435-1441. (Pubitemid 16156253)
39. Waggoner SN, Daniels KA, Welsh RM (2013) Therapeutic depletion of natural killer cells controls persistent infection. Journal of virology.
40. Hummel S, Wilms D, Vitacolonna M, Zoller M (2002) Donor T cell and host NK depletion improve the therapeutic efficacy of allogeneic bone marrow cell reconstitution in the nonmyeloablatively conditioned tumor-bearing host. Journal of leukocyte biology 72: 898-912. (Pubitemid 35365163)